High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1688-1697

  Schneider Stock, Regine ^a   Boltze, Carsten ^a   Lasota, Jerzy ^a   Miettinen, Markku ^a   Peters, Brigitte ^a   Pross, Matthias ^a   Roessner, Albert ^a   Günther, Thomas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16INK4A;

ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; GASTROINTESTINAL STROMAL TUMOR; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TUMOR VOLUME; ADULT; AGED; CANCER STAGING; FEMALE; GASTROINTESTINAL TUMOR; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; STROMA CELL; SURVIVAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; GASTROINTESTINAL NEOPLASMS; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); STROMAL CELLS; SURVIVAL;

EID: 0038135029     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.101     Document Type: Article

References (41)

1. Miettinen M, Lasota J: Gastrointestinal stromal tumors-definition, clinical, histological, immimohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12, 2001
2. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465, 2002
3. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
4. Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cell of Cajal. Am J Pathol 152:1259-1269, 1998
5. Miettinen M, Sobin LH, Sarlomo-Rikala M: Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 13:1134-1142, 2000
6. Ernst SI, Hubbs AE, Przygodzki RM, et al: KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 78:1633-1636, 1998
7. Lasota J, Jasinski M, Sarlomo-Rikala M, et al: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53-60, 1999
8. Lux ML, Rubin BP, Biase TL, et al: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791-795, 2000
9. Lasota J, Wozniak A, Sarlomo-Rikala M, et al: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. Am J Pathol 157:1091-1095, 2000
10. Rubin BP, Singer S, Tsao C, et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121, 2001
11. Taniguchi M, Nishida T, Hirota S, et al: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59:4297-4300, 1999
12. Corless CL, McGreevey L, Haley A, et al: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567-1572, 2002
13. Miettinen M, El-Rifai W, Sobin LII, et al: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum Pathol 33:478-483, 2002
14. Cunningham RE, Abbondanzo SL, Chu WS, et al: Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol 9:19-23, 2001
15. Panizo-Santos A, Sola I, Vega F, et al: Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 8:133-144, 2000
16. Sakurai S, Fukayama M, Kaizaki Y, et al: Telomerase activity in gastrointestinal stromal tumors. Cancer 83:2060-2066, 1998
17. El-Rifai W, Sarlomo-Rikala M, Andersson LC: DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance. Cancer Res 60:3899-3903, 2000
18. Gunawan B, Bergmann F, Hoer J, et al: Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastroinestinal stromal tumors. Hum Pathol 33:316-321, 2002
19. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al: Chromosomal aberrations in malignant gastrointestinal stromal tumors: Correlation with C-KIT gene mutation. Cancer Genet Cytogenet 128:24-30, 2001
20. Esteller M, Herman JG: Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196:1-7, 2002
21. Esteller M, Corn PG, Maylin SB, et al: A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229, 2001
22. Merlo A, Herman JG, Mao L, et al: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p 16/ CDKN2/MTS1 in human cancers. Nat Med 1:686-692, 1995
23. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many cancer types. Science 264:436-440, 1994
24. INK4 in human cancer. Proc Natl Acad Sci U S A 91:11045-11049, 1994
25. Herman JG, Graff JR, Myöhänen S, et al: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826, 1996
26. INK4a. Exp Cell Res 237:7-13, 1997
27. Kim NG, Kim JJ, Ahn JY, et al: Putative chromosomal deletions on 9p, 9q and 22q occur preferentially in malignant gastrointestinal stromal tumors. Int J Cancer 85:633-638, 2000
28. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: A Laboratory Manual (ed 4). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
29. Goldman D, Merril CR: Silver staining of DNA in polyacrylamide gels: Linearity and effect of fragment size. Electrophoresis 3:24-26, 1982
30. Schneider-Stock R, Radig K, Roessner A: Loss of heterozygosity on chromosome 9q21 (p16 gene) uncommon in soft-tissue sarcomas. Mol Carcinog 18:63-65, 1997
31. Gunther T, Schneider-Stock R, Hackel C, et al: Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin Cancer Res 6:1811-1818, 2000
32. Landberg G, Nielsen NH, Nilsson P, et al: Telomerase activity is associated with cell cycle dysregulation in human breast cancer. Cancer Res 57:549-554, 1997
33. Sherr CJ: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731-737, 2001
34. Liu Q, Yan YX, McClure M, et al: MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene 10:619-622, 1995
35. Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8:514-519, 2002
36. Burri N, Shaw P, Bouzourene H, et al: Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 81:217-229, 2001
37. Wong YF, Chung TK, Cheung TH, et al: Methylation of p16INK4a in primary gynecologic malignancies. Cancer Lett 136:231-235, 1999
38. Serrano J, Goebel SU, Peghini PL, et al: Alterations in the p16INH4a/ CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 85:4146-4156, 2000
39. Tsutsumi M, Tsai YC, Gonzalgo ML, et al: Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. Oncogens 17:3021-3027, 1998
40. Seike M, Gemma A, Hosoya Y, et al: Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. Clin Cancer Res 6:4307-4313, 2000
41. Esteller M, Gonzalez S, Risques RA, et al: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19:299-304, 2001